Viral myocarditis caused by Coxsackievirus B (CVB) infection is a severe inflammatory disease of the myocardium, which may develop to cardiomyopathy and heart failure. No effective medicine is available to treat CVB infection. Here we evaluated the anti-CVB effect of N-acetyl cysteine (NAC), a widely used antioxidant. NAC significantly alleviated myocarditis and improved the overall condition of CVB type 3 (CVB3)-infected mice. Importantly, NAC treatment suppressed viral replication in both myocardium and cell culture. We show that NAC inhibited CVB3 replication when it was applied at the early stage of CVB3 infection. NAC's antiviral mechanism, while independent of its antioxidant property, relies on its inhibition on caspase-1 activation, since the knockdown of caspase-1 blocked CVB3 replication.
Introduction
Myocarditis is defined as the inflammation of myocardium, which can be caused by the infection of various pathogens 1, 2 . Viral myocarditis is a common disease which represents the significant cause of cardiac death, especially among young adults [2] [3] [4] . Coxsackievirus B (CVB), a single-stranded, positivesensed RNA virus in the Enterovirus genus of Picornaviridae family, is the leading pathogen that causes myocarditis 5, 6 . Although acute viral myocarditis is often subclinical and the recovery may be spontaneous, severe myocarditis with the necrosis of myocardium and fatal ventricular tachycardia has been observed 7, 8 . Increasing evidence has suggested that a substantial number of patients with viral myocarditis progress to dilated cardiomyopathy, which may lead to heart failure and cardiac death 9 . The pathogenesis of CVB infection has not been completely understood 5, 10 . Treatment to viral myocarditis relies primarily on supportive care due to the lack of specific antiviral agents.
CVB includes six serotypes (CVB1 -CVB6). The genome of CVB is a single-stranded, positive-sensed RNA about 7.4 kb, which encodes four capsid proteins (VP1 -VP4) and six nonstructural proteins (2A, 2B, 2C, 3A, 3C, and 3D). 3D is the RNA-dependent RNA polymerase (3D pol ) which is responsible for the replication of viral genome, while 2A and 3C are viral proteases (2A pro and 3C pro ) which trans-cleave the viral polyprotein and are required for the maturation and assembly of viral particles 5 . Studies have shown that 2A pro and 3C pro also cleave and degrade cellular proteins involved in translation and innate immunity such eukaryotic initiation factor 4G (eIF4G), mitochondrial antiviral-signaling protein (MAVS), and retinoic acid inducible gene I (RIG-I) 11, 12 . Through cleaving eIF4G, a key component in the pretranslation initiation complex, CVB shuts down the cap-dependent translation and hence blocks cellular protein synthesis 13 . Viral translation, however, is not affected, because picornaviral RNA is uncapped and the translation initiation uses an internal ribosome entry site (IRES) in the 5-untranslated region (5'-UTR) 14, 15 To benefit viral replication, CVB also manipulates other cellular machineries such as ubiquitin proteasome system (UPS) 16, 17 . UPS is an important non-lysosomal protein degradation mechanism for eukaryotic cells, and it is involved in fundamental cellular processes 18 . Proteins targeted for destruction by UPS are often short-lived regulatory proteins such as cyclins, p53, and p57 18, 19 . In addition, UPS also targets misfolded proteins with abnormal configurations which could be harmful to the cell. Upon ubiquitination, a chain of multiple copies of ubiquitin (UB) is linked to the substrate protein, which is then degraded by 26S proteasome [18] [19] [20] . It has been demonstrated that UPS is utilized during CVB3 infection, while dysregulated UPS showed negative impact on CVB3 replication 16, 17 .
CVB infection typically causes inflammatory injury of the myocardium characterized by the damage of cardiac muscles and the infiltration of inflammatory cells 1, 21 . The rapid production of proinflammatory cytokines has been seen in both patients and CVB-infected mice shortly after the infection of CVB 22, 23 .
These cytokines include IL-6, IL-1β, and TNF-α 23, 24 . Enhanced production of inflammatory cytokines and chemokines is associated with severe impaired cardiac function and myocardial fibrosis 25 .
Proinflammatory cytokines also lead to aberrant mitochondrial metabolism of the cardiomyocytes, which further contributes to the dysfunction of the CVB-infected heart 26 . The maturation and release of the proinflammatory cytokines IL-1β and IL-18 require active caspase-1, which proteolytically cleaves the precursors of IL-1β and IL-18 27 .
Caspase-1, one of the aspartic acid-specific cysteine proteases, is best known for its role as the inflammation initiator 28, 29 . Caspase-1 is synthesized as zymogen and becomes active when recruited into inflammasomes in response to various pathogen-associated molecular patterns (MAMP) or dangerassociated molecular patterns (DAMP) 30 . Once recruited into the inflammasome, caspase-1 undergoes autoproteolysis to form the active heterodimer composed of caspase-1 p20 and p10 27, 28 . Active caspase-1 cleaves the precursors of IL-1β, IL-18, and IL-33, which then released from the cell to trigger inflammation 27 . The generation of pro-inflammatory cytokines represents the first line of the defense mechanism against the invasion of pathogens 31, 32 . Excessive caspase-1 activation, however, is involved in various pathological conditions such as cardiovascular disease 33 , chronic kidney disease 34 , and inflammatory bowel disease 35 .
In addition to triggering pyroptosis and inflammation, caspase-1 might be involved in the pathogenesis of viral infection. During the infection of herpes simplex virus and vaccinia virus, caspase-1 suppresses the stimulator of interferon genes (STING)-mediated production of interferon (IFN) 36 . Zika virus evades the host immune response through stabilizing caspase-1 by its nonstructural protein NS1, leading to the cleavage of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) 37 .
Caspase-1 induces cell death contributes to the depletion of CD4 + T cells in human immunodeficiency virus (HIV)-infected patients 38 . We previously demonstrated that CVB infection induced caspase-1 activation. surprisingly, we found that inhibition of caspase-1 with specific inhibitors not only alleviated the myocardial inflammation but also significantly inhibited viral replication, suggesting a novel therapeutic strategy against CVB-induced myocarditis 39 . N-acetyl cysteine (NAC), an amino acid derivative, is among the list of essential medicines issued by the World Health Organization 40 . As the precursor of glutathione, an important cellular antioxidant molecule, NAC has been used for the treatment of various conditions with oxidative stress such as paracetamol overdose 41, 42 , traumatic injury 43 , as well as liver and renal failure 44, 45 . In vitro study has demonstrated that the addition of NAC to cultured cells suppresses the replication of EV71 46 . NAC could also alleviate the liver injury caused by Dengue virus infection by promoting the production of interferon 47 . So far there is no report available on the role of NAC in the therapy of CVB infection.
The present study aims to investigate the potential application of NAC in the CVB type 3 (CVB3)-induced myocarditis. Interestingly, our in vivo and in vitro data reveal that NAC can simultaneously suppress CVB3 replication and inflammatory response through blocking caspase-1 and viral proteases. Given that NAC is clinically approved medicine, NAC may therefore be a promising agent for the treatment of CVB-related myocarditis.
Results

NAC shows cardio-protective and antiviral effect for mice infected with CVB3
NAC is an established antioxidant. Its anti-inflammatory property has also been well demonstrated 48, 49 . Viral myocarditis caused by CVB3 infection is primarily the inflammation of myocardium 1 . Treatment with anti-inflammatory medicines improved heart function and reduced the serum level of proinflammatory cytokine TNF- 50, 51 . Motivated by the anti-inflammatory feature of NAC, we treated CVB3-infected mice with NAC, anticipating that NAC would suppress myocardial inflammation.
To this end, we used CVB3-infected Balb/c mice, the typical mouse model for the study of CVB3 infection. Newborn Balb/c mice within 3-to 5-day-old were infected with 10 6 TCID 50 of CVB3 intraperitoneally. Mice were given 15 mg/kg (body weight) of NAC intraperitoneally twice a day for five consecutive days starting at 12 h of post-infection (p.i.). Control mice was infected with CVB3 and treated with phosphate buffered saline (PBS). At day 5 of p.i., mice were euthanized and mouse hearts were collected and subjected to histopathological observation. Figure 1 , CVB3 infection caused debilitating changes of the mice manifested by the coarse fur ( Figure 1A ) and the decline of body weight ( Figure 1B ). One third (3/9) of the mice infected with CVB3 were alive at day 5 of p.i. In contrast, CVB3-infected mice treated with NAC showed improved fur appearance and slowly increased body weight. Two third (6/9) of the CVB3-infected mice treated with NAC were still alive at day 5 of p.i. ( Figure 1C ).
As shown in
Histopathological analysis shows that the infection of CVB3 resulted in significant myocardial injury represented by the damaged myofibril foci and the infiltration of inflammatory cells, while the treatment of NAC dramatically improved the morphology of myocardium with significantly mild myocardial injury and the diminished infiltration of mononuclear cells ( Figure 1D ), demonstrating that NAC has cardioprotective effect. The results of ELISA show that the levels of the proinflammatory cytokines including TNF-α, IL-6, IL-1β, and IL-18 were significantly reduced in the CVB3-infected myocardium with NAC treatment ( Figure 1E ). Collectively, these data indicate that NAC clearly inhibited cardiac inflammation resulted from CVB3 infection.
The improved morphology and inflammation of the myocardium of CVB3-infected mice with NAC treatment motivated us to ask the question how the viral load was changed. To show viral replication, total RNAs and proteins were extracted from the myocardium. Viral genome and VP1 of CVB3 were determined by RT-PCR and Western blotting, respectively. The abundance of viral genome ( Figure 1F ) and the level of VP1 ( Figure 1G ) in the myocardium infected with CVB3 were clearly decreased, indicating that viral replication is suppressed. Collectively, these data show that NAC exerts antiinflammatory and antiviral effect for CVB3-induced myocarditis.
NAC inhibits the replication of CVB3 in HeLa cells
We next used in vitro approaches to confirm the antiviral effect of NAC. HeLa cells were infected with CVB3 at MOI of 1 for 24 h. NAC was added to the culture medium at the same time as viral infection began. As shown in Figure 2 , the application of NAC significantly suppressed the cytopathic effect induced by CVB3 infection (Figure 2A ) and improved the viability of the cells ( Figure 2B ). Importantly, compared to the CVB3-infected cells without NAC treatment, viral 3D RNA polymerase (3D pol ) ( Figure   2C ), viral RNA ( Figure 2D ), as well as the production of virions ( Figure 2E ) were significantly reduced in the cells treated with NAC. These results indicate that NAC exerts potent inhibition on CVB3 replication.
To further understand the antiviral activity of NAC during the course of CVB3 infection, HeLa cells were infected with CVB3 (MOI =1) for 9 h, and NAC was added to the culture medium at various time points of post-infection (p.i.) ( Figure 1F ). When NAC was added at 2 h of p.i. or earlier, the synthesis of viral 3D pol was almost completely blocked. When NAC was added at 3 or 4 h of p.i., markedly reduced levels of 3D pol were still observed. However, when NAC was added to the culture medium at 5 h of p.i., the synthesis of viral 3D pol was not affected. These data demonstrate that NAC shows antiviral effect when it is applied at the early stage of CVB3 replication.
We found that the maximum inhibition on CVB3 replication was achieved ( Figure 2D ), when NAC was used at 20 mM. In the meantime, cell viability was still maintained ( Figure 2B ). Thus, 20 mM of NAC was used for the remaining in vitro experiments in this study.
The antiviral effect of NAC is independent of its antioxidant activity
NAC is well-known as ROS scavenger, since it is believed to be the precursor of glutathione, an important antioxidant of the cell 52 . It has been reported that certain plant RNA virus exploits the increased ROS of the host cell to promote viral replication 53 . Moreover, inhibited generation of ROS by NAC has negative impact on the replication of EV71 in cultured cells 46 . Thus, we asked the question whether or not the suppressed replication of CVB3 was due to the reduced generation of ROS as a result of NAC treatment.
To this end, HeLa cells were cultured in the medium containing NAC at 20 mM/L for 1 or 2 h prior to the infection of CVB3, and then cells were infected with CVB3 and grown in the medium without the supplementation of NAC for 24 h. As shown in Figure 3A , massive production of ROS was seen in the cells infected with CVB3. The generation of ROS was markedly reduced in the CVB3-infected cells with NAC pretreatment ( Figure 3A and B) , while the synthesis of viral 3D pol was not suppressed ( Figure 3C ).
These data indicate that the antioxidant property of NAC does not contribute to its antiviral activity.
Moreover, these data also suggest that NAC does not block virus entry in the course of CVB3 infection, since CVB3 was efficiently replicated in the cells pretreated with NAC ( Figure 3C ).
NAC directly inhibits the activation of caspase-1
Viruses are obligate intracellular pathogens which utilize cellular machinery to synthesize macromolecules and to achieve efficient replication. Thus, we asked whether NAC regulates cellular components which are essential to viral replication. Our previous study demonstrated that selective caspase-1 inhibitor not only alleviated the inflammation caused by CVB3 infection, but also showed antiviral effect 39 , suggesting the essential role of caspase-1 in CVB3 infection. In the present study, we observed the reduced production of pro-inflammatory cytokines including TNF-, IL-6, IL-1, and IL-18 during the infection of CVB3 in both mouse myocardium ( Figure 1E ) and HeLa cells ( Figure S1A ) treated with NAC. Given that caspase-1 is required for the maturation of both IL-1 and IL-18, the reduced IL-1 and IL-18 implies that caspase-1, its precursor or active form, is down-regulated by NAC treatment.
To this end, we infected HeLa cells with CVB3 (at MOI =1) and determined caspase-1 level at various time points of post-infection. As shown in Figure 4A , dramatically increased level of caspase-1 p20, one of the active fragments of caspase-1, was seen in the cells at 12 h of post-infection. As we have demonstrated previously 39 , procaspase-1 and NLRP3, the critical constituents of NLRP3 inflammasome, were also increased due to CVB3 infection ( Figure 4A ).These data show that CVB3 infection not only induces the activation of caspase-1, but also increases the level of procaspase-1.
Although the role played by caspase-1 in CVB3 replication remains to be further studied, our data pointed the possibility that the anti-CVB3 effect of NAC might be related to its impact on caspase-1 activation. To address the question if NAC influences the activity of caspase-1 in the context of CVB3 infection, HeLa cells were infected with CVB3 and treated with NAC or caspase-1 inhibitor (VX765) for 12 h. The caspase-1 precursor and its active form (p10) were determined. CVB3 infection significantly increased both the precursor and active caspase-1 p10 ( Figure 4B and C), while the treatment of NAC or caspase-1 inhibitor clearly reduced procaspase-1 as well as the active caspase-1 (p10) ( Figure 4B and C).
Importantly, the diminished active caspase-1 coincided with the disappearance of viral 3D pol ( Figure 4C ).
These data clearly show that NAC down-regulates caspase-1, and this action may contribute to the anti-CVB3 effect of NAC.
We next tried to answer the question how NAC exerts inhibition on caspase-1 activation. NAC is a thiolcontaining chemical and the pro-drug of cysteine which provides sulfhydryl during its reactions 54 . Thus, we postulated that the NAC's inhibition on caspase-1 activity might be associated with the chemical character of this molecule, which allows it to form disulfide bonds with the cysteine residues of caspase-1 55 . To address this possibility, we performed in vitro study by testing the impact of NAC on the recombinant active caspase-1 (ab39901, Abcam; Cambridge, MA). 10 units of the recombinant caspase-1 was incubated with 50 nM of NAC at 37°C for 2 h, and caspase-1 activity was measured. As shown in Figure 4D , NAC treatment remarkably reduced the activity of caspase-1, indicating that NAC directly inhibits the activity of caspase-1.
To provide evidence that caspase-1 plays a role in CVB3 infection, we performed knockdown study using the siRNA of procaspase-1. HeLa cells were transfected with siRNA of procaspase-1 for 36 h and infected with CVB3 for 12 h. We found that the synthesis of 3D pol of CVB3 was almost completely blocked in the cells with the knockdown of procaspase-1, indicating that caspase-1 is required for CVB3 replication.
Collectively, the above data show that the anti-CVB3 mechanism of NAC relies, at least partly on inhibiting caspase-1 activation, which is required for CVB3 replication.
NAC promotes the degradation of procaspase-1 through ubiquitin-proteasome pathway
Even though the mechanism by which NAC inhibits caspase-1 activation has been studied ( Figure 4C -E), we still need to answer the question how NAC down-regulates procaspase-1. To this end, we first determined the protein levels of procaspase-1 in the cells treated with MG132 or infected with CVB3 in the presence or absence of NAC. As shown in Figure 5 , MG132 treatment obviously increased the levels of both procaspase-1 and procaspase-3 ( Figure 5A -C), indicating that procaspases, at least for procaspase-1 and procaspase-3, are degraded through UPS. CVB3 infection also increased the levels of the precursors of both caspase-1 and caspase-3 ( Figure 5A -C). Importantly, NAC treatment downregulated the level of procaspase-1 in the cells with either MG132 treatment or CVB3 infection, suggesting that NAC promotes the degradation of procaspase-1.
To further evaluate whether the expression of procaspase-1 is changed at transcriptional level, HeLa cells were infected with CVB3 in the presence of NAC for 12 h, and mRNA level of procaspase-1 was determined by RT-qPCR. As shown in Figure 5D , the abundance of procaspase-1 mRNA was not changed in the cells infected with CVB3 with or without the treatment of NAC, indicating that the transcription or stability of procaspase-1 mRNA is not interfered. These data also suggest that the protein degradation mechanism might play a role for the decline of procaspase-1 with NAC treatment.
26S proteasome is the protein assembly that mediates the degradation of polyubiquitin-conjugated proteins outside of lysosome. To show whether NAC regulates protein degradation through UPS, HeLa cells were treated with MG132 or infected with CVB3 for 12 h in the presence or absence of NAC.
Ubiquitin-conjugated proteins were determined. As shown in Figure 5E To confirm that NAC promotes the degradation of procaspase-1, HeLa cells were treated with cycloheximide (CHX) (Jinpin Chemical, Shanghai, China), the inhibitor of protein synthesis. The amount of procaspase-1 was determined at various time points after CHX treatment. As shown in Figure 5F and G, within 10 h of CHX treatment, the amount of procaspase-1 has no obvious change. In contrast, in the cells pre-treated with NAC for 12 h, procaspase-1 disappeared at 6 h of CHX treatment, indicating that NAC accelerates the degradation of procaspase-1.
NAC inhibits viral proteases
The enterovirus proteases of 2A pro and 3C pro , which are essential for processing viral polyprotein during viral replication, are chymotrypsin-like cysteine proteases 5 . Motivated by our finding that NAC inhibits the activity of caspase-1, we asked the question if NAC also shows inhibitory effect on viral proteases, since viral proteases, like caspase-1, are also cysteine proteases 56 . In addition to processing viral polyproteins, 2A pro and 3C pro target multiple cellular proteins including eIF4G 13 Figure 4A) . Similarly, the cleavage of TDP43 was observed in the cells expressing EGFP-3C, which generated a fragment in 35 kDa.
NAC treatment for the cells expressing EGFP-3C blocked the cleavage of TDP-43 ( Figure 6B ). These results show that NAC suppresses the activity of viral 2A pro and 3C pro .
Discussion
The infection of CVB3 can cause severe and life-threatening viral myocarditis, which may progress to dilated cardiomyopathy 9 . Until now, no effective antiviral medications are available for the treatment of CVB3 infection 58 . The present study demonstrated that NAC, an antioxidant and the prodrug of cysteine, exhibits antiviral and anti-inflammatory effect against CVB3 infection both in vitro and in vivo. The antiviral mechanism of NAC is related to its inhibiton on caspase-1 and viral proteases. Based on this study, we propose that NAC could potentially be a safe and effective therapeutic option for myocarditis caused by CVB3 infection.
Myocarditis is defined as the inflammation of the cardiac muscle. The histological presentations of viral myocarditis caused by CVB3 infection include the necrosis of cardiomyocytes and the infiltration of lymphocytes or monocytes 7, 59 . Cardiac inflammation caused by CVB3 infection is characterized with increased production of pro-inflammatory cytokines and the activation of nuclear factor kappa B (NF-kB) 60 . Because of the lack of specific antiviral medicine, supportive care is still the primary treatment to CVB3-induced myocarditis 58 .
NAC, as a water-soluble and thiol-containing antioxidant, is the established antidote for the treatment paracetamol overdose 61 . It is recommended as the therapeutic option for conditions characterized by the generation of ROS 62 . The -SH group of NAC confers it with the character of reducing disulfide bonds.
Thus, NAC is widely used as mucolytic medicine to reduce the viscosity of the mucus generated during respiratory diseases such as COPD, cystic fibrosis, and chronic bronchitis 63, 64 . Except as antioxidant, NAC also possesses anti-inflammatory activity through inhibiting the activation of NF-B 65 . The application of NAC for diabetic patients with dialysis significantly suppressed the activation of NF-B 48 .
The inflammatory character of viral myocarditis and the anti-inflammation activity of NAC motivated us to use NAC to combat the devastating inflammatory response induced by CVB3 infection. We were also encouraged by the report that blocking IL-1β-mediated signaling pathway led to significantly inhibited inflammation, viral replication, and cardiac changes 66 . Thus, we used NAC to treat mice with viral myocarditis induced by CVB3 infection. We initially anticipated that NAC would alleviate myocardial inflammation and improve the overall condition of the infected mice. Unexpectedly, we found that, in addition to its anti-inflammation and cardio-protective effect, NAC also showed remarkable inhibition on CVB3 replication. To understand its antiviral mechanism, we started by determining the activity of caspase-1, since our previous study showed that CVB3 replication was inhibited by caspase-1 inhibitor 39 .
Indeed, we found that NAC not only inhibited caspase-1 activation, but also reduced the level of procaspase-1. We further demonstrated that the reduced procaspase-1 was due to its increased degradation through ubiquitin-proteasome pathway, as a result of NAC treatment. We also determined the impact of NAC on the activity of viral 2A pro and 3C pro , because these proteases, similar to caspase-1, are also cysteine proteases. Our data show that in the presence of NAC, viral proteases lost their proteolytic activity towards cellular proteins eIF4G and TDP-43, respectively. Collectively, this study demonstrated that NAC exerts antiviral and cardio-protective effect for CVB3-induced myocarditis. The antiviral mechanism of NAC is associated with its inhibition on caspase-1 as well as viral proteases.
Obviously, our results contradict to the study by Si et al 67 , in which no antiviral effect of NAC was observed against CVB3 infection in cultured cells. This difference is likely caused by the intrinsic reactivity of NAC, in which cysteine is oxidized to cystine at the contact of air in neutral or alkaline solution (Sigma-Aldrich, https://www.sigmaaldrich.com/catalog/product/sigma/a9165). Therefore, the concentration of NAC is gradually decreasing in working solution. This could be the reason that NAC lost its inhibitory effect on CVB3 replication. To maintain the precise concentration of NAC, we stored NAC at -80C and prepared fresh working solution for each application.
For the mouse model of viral myocarditis, we show that when NAC was given at relative low dosage (15 mg/kg body weight, twice a day), significant cardio-protective and antiviral effect were achieved.
According to the clinical application of NAC for the treatment of acetaminophen overdose or gentamycin toxicity, intravenous administration of NAC at 1200 mg twice a day is well tolerated 62, 68-70 . Therefore, our results suggest that NAC could be a safe option for the treatment of CVB3 infection. However, further laboratory and clinical studies are needed.
In this study, we showed that when 20 mM of NAC was used in cell culture, maximum antiviral effect was obtained, while the cell viability was largely maintained. It is worth to note that the half-life of NAC is typically short 71 . According to an in vitro study, only 18% free NAC was retained after incubating in serum containing medium for 24 h 72 . It is believed that NAC is rapidly metabolized due to its incorporation on to proteins. In spite of its short half-life, we observed its antiviral effect at 24 h after the addition of NAC in cell culture. The antiviral and anti-inflammatory effect were also confirmed in mouse model of viral myocarditis. These data suggest that the antiviral mechanism of NAC may involve its influence on cellular and viral components, leading to the inhibition of inflammation and viral replication.
Similar to other picornaviruses, CVB3 infection induces oxidative stress 51, 67 . Evidence also shows that ROS is harnessed by certain plant RNA virus to facilitate viral replication 53 . Therefore, we evaluated whether the antioxidant property of NAC plays a role in its antiviral mechanism. Unlike the report about EV71 73 , in which the reduction of ROS suppressed the production of viral progeny, we demonstrated that the antiviral effect of NAC is independent of its antioxidant function.
The anti-inflammation effect of NAC inspired us to evaluate its influence on caspase-1, since we previously showed that caspase-1 inhibitor suppressed CVB3 replication 39 . Here we demonstrated that NAC inhibits the activity of caspase-1 and down-regulates the level of procaspase-1 through regulating UPS. NAC is the synthetic precursor of cysteine. Both NAC and cysteine contain free sulfhydryl group which enable these molecules to function as nucleophilic and antioxidant. They can also form disulfide bonds with thiol-containing molecules such as the cysteine residues of proteins 74 . In this study, we found that the activity of caspase-1 was directly inhibited by NAC ( Figure 4F ). This is likely the result of the reaction between NAC and the cysteine residue in the catalytic site of caspase-1, leading to the formation of disulfide bond and the conformational change of caspase-1. Consequently, caspase-1 is inactivated. This point of view is supported by the fact that the majority of caspase-1 inhibitors covalently interacting with the active site cysteine residue of the enzyme 75, 76 . For example, VX-765, the inhibitor of caspase-1, functions through reversible covalent modification of the catalytic cysteine residue of the enzyme 75 . Similarly, NAC's inhibition on the proteases of CVB3 may also involves the same mechanism, because viral proteases also contain cysteine residue in their catalytic sites 56 . Studies on hepatitis A virus (HAV) and human rhinovirus (HRV), which are important pathogens in the picornavirus family, showed that thiol-reactive groups such as iodoacetamides and beta-lactones can be used to inhibit the activity of 3C pro of HAV and HRV 77 .
We further demonstrated that UPS is involved in the antiviral mechanism of NAC. UPS, the important protein degradation machinery, participates in almost all cellular activities, and it plays crucial roles in maintaining the proteostasis of mammalian cells 18 . Evidence shows that UPS is exploited by CVB3 17, 78 , while the precise role of UPS in CVB3 replication remains unknown. Moreover, how NAC would influence UPS in the context of CVB3 infection is unclear. In this study, we found that the protein levels of both procaspase-1 and procaspase-3 were increased by the treatment of MG132 ( Figure 5A-C) , the proteasome inhibitor, indicating that procaspases, at least for procaspase-1 and procaspase-3, are degraded through UPS. Importantly, NAC treatment blocked the accumulation of caspase-1 induced by either MG132 or CVB3 infection, and the decline of procaspase-1 was coincided with the significantly reduced production of viral 3D pol (Figure 5A-C) . We further show that the reduction of procaspase-1 is not due to the suppressed gene expression, because the mRNA level of procaspase-1 was not changed in the cells infected with CVB3 or treated with NAC ( Figure 5D ). Instead, we demonstrated that NAC regulates UPS and promotes the degradation of procaspase-1 ( Figure 5E-G) . Similarly, the degradation of p53, a cell cycle regulatory protein which is degraded through UPS, was also accelerated by the treatment of NAC (supplementary Figure S2 ).
How exactly can NAC regulate UPS remains unknown. Although our data showed that NAC accelerated the degradation of procaspase-1, we have no direct evidence that demonstrates the influence of NAC on the process of ubiquitination or proteasomal degradation. Our data suggest that NAC accelerates the degradation of the precursors of pan-caspases. In consistent to this postulation, a study has shown that E3 ligase TRAF2 exerts negative effect on the activity of caspase-8 79 . A previous study suggested that NAC improves the process of protein folding, which results in the disappearance of ubiquitinated proteins, while NAC did not subvert the inhibition of MG132 on proteasome 80 . Nonetheless, if protein degradation were not involved in the decline of procaspase-1 in the presence of NAC, there would be no accelerated reduction of this protein when cells were treated with CHX, the inhibitor of protein synthesis ( Figure 5F and G) .
There is still one question which remains unanswered. If the degradation of procaspase-1, which would lead to the further inhibition of caspase-1, is not favorable for CVB3 replication, the suppressed degradation of procaspase-1 would facilitate viral replication. In contrast, MG132, the proteasome inhibitor which blocks the degradation of procaspase-1, also has anti-CVB3 effect 81 . These data imply that capase-1 and UPS may exert their impact on CVB3 replication through distinct mechanisms.
Nonetheless, the role of UPS in CVB3 infection needs to be clarified.
The limitation of this study is that we have not demonstrated the role of caspase-1 in CVB3 infection, although we believe that the activation of caspase-1 is crucial for CVB3 replication, since viral replication was almost blocked when procaspase-1 was knocked down. Furthermore, although NAC has been used in clinical practice for several decades as the prodrug of cysteine and the precursor of glutathione, the mechanisms underlying its therapeutic activity towards various conditions are still unclear. Evidence has shown that NAC influences multiple signaling pathways of the cell such NF-B 82 , p38 MAPK 83 , JNK 84 , and nitric oxide 85 . Thus, our study certainly cannot exclude the possibility that critical cellular pathways might also contribute to the antiviral effect of NAC.
In conclusion, this study demonstrated that NAC exerts antiviral and anti-inflammatory effect against CVB3 infection. NAC treatment clearly alleviated the myocarditis and suppressed CVB3 replication. The antiviral mechanism of NAC is related with its inhibition on caspase-1 and viral proteases (Figure 7) .
Thus, NAC might be a safe therapeutic option for the treatment of myocarditis caused by CVB3 infection.
Materials and Methods
Ethical approval
All protocols were approved by the Ethics Committee of Harbin Medical University. All experimental procedures were conducted in accordance with the regulation on the use and care of laboratory animals for research.
Mice
Newborn Balb/c mice were purchased from the Laboratory Animal Center of Harbin Medical University (Harbin, China). Mice were housed in specific pathogen-free environment at the temperature of 25 ± 1 °C and 40-50% humidity. Mice were allowed to access food and water ad libitum. To generate animal myocarditis model, newborn mice (n = 6-9 mice per group) were infected with 10 6 TCID 50 of CVB3 by intraperitoneal injection once at day 3-5 after birth. Control mice were injected with phosphate buffered saline (PBS) (Biosharp, Hefei, China). Mice were monitored and euthanized at day 5 of post-infection (p.i.). Mouse ventricles were collected and subjected to histological examination, RNA and protein extraction, and ELISA. Total of 96 new-born mice were used. Body weight change of each mouse was calculated according to the formula: (body weight -body weight of previous day) /5 day.
Cell culture
HeLa cells were kindly provided by the Department of Medical Genetics of Harbin Medical University.
Cells were grown in a humidified incubator with 5% CO 2 at 37 °C. Cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher, Shanghai, China) supplemented with 10% (v/v) fetal bovine serum (FBS) (Bioindustry, Israel), penicillin (100U/L), and streptomycin (100 U/L). Cells were provided with fresh medium every 2-3 day3. Cells infected with viruses were grown in the medium containing 2%FBS.
Virus
CVB3 woodruff was kindly provided by the Scrips Institute (San Diego, USA) as previously described 86 .
Virus was amplified in HeLa cells and stored at -80°C. Virus stock was subjected to 3 times of freeze-thaw cycle and centrifuged 5 min at 1000 rpm to collect to the supernatant. Virus was titrated. Virus stock was passaged no more than three times to exclude possible cell adaptation. The 50% tissue culture infective dose (TCID 50 ) of CVB3 used in this study was 10 7 /100 µL. HeLa cells at the confluency of 70% were infected with CVB3 at 1 of multiplicity of infection (MOI). Cells were allowed to absorb viruses for 1 h, and then the supernatant was removed and replaced with fresh media.
NAC treatment
NAC (A9165; Sigma-Aldrich, St. Louis, MO) was dissolved in PBS. Aliquoted solution of NAC was stored at -80°C and used only once to avoid oxidation. HeLa cells infected or mock-infected with CVB3 were cultured in the medium containing 20 mM NAC for various time periods. For in vivo experiments, mice were infected or mock-infected with 10 3 TCID50 CVB3. 15 mg/kg (body weight) of NAC was given intraperitoneally to mice twice a day beginning at 12 h of p.i.. Mice were euthanized at the end of day 5 of p.i..
Transfection
Plasmids expressing the non-structural protein 2A or 3C of CVB3 (designated as pEGFP-2A and pEGFP-3C, respectively) and the control plasmid pEGFP-C1 were constructed as described previously 12 
RNA extraction and real-time quantitative PCR (RT-qPCR)
Cells were cultured in 6-well plate to 90% confluency and total RNA was extracted by Trizol (Life Technologies, Carlsbad, CA) and RT-qPCR was performed following the instruction of the manufacturer.
Briefly, 1 μg of total RNA was reverse transcribed in a reaction of 10 µL with 4μL of 5×TransScript All-in-One SuperMix (Transgen, Beijing, China). Quantitative PCR was performed by adding 1 μL of cDNA, 0.4 μM of forward and reverse primers, 10 μL of 2×TransStart Top Green qPCR SuperMix (Transgen, Beijing, China), and RNase-free water to make 20 µL of total reaction. PCR reaction was carried out in LightCycler 96 (Roche) for 45 cycles of denaturation at 94 °C for 5 s，annealing at 55 °C for 15 s，and extension at 72°C for 1 min. The relative RNA amount was calculated with the 2 -ΔΔCT threshold cycle (CT) method and normalized to the amount of GAPDH 87 . All reactions were carried out on triplicate. Primers were synthesized by Genewiz (Suzhou, China) and the sequences of the primers are follows: for CVB3, forward primer 5′-GCACACACCCTCAAACCAGA-3′ and reverse primer 5′-ATGAAACACGGACACCCAAAG-3′ ; for GAPDH, forward primer 5′-TGCACCACCAACTGCTTAGC-3′ and reverse primer 5′-GGCATGGACTGTGGTCATGAG-3′.
Western blot
To extract proteins from cultured cells, cells grown in 6-well plate to 90% confluency were treated with 100 μL RIPA (Beyotime, Wuhan, China) containing protease inhibitor PMSF (v/v at 100:1) (Beyotime) for 20 min on ice. Cells were scraped from the culture plate and centrifuged at 4°C for 20 min to collect the supernatant. To extract proteins from tissue, mouse heart was collected and atrium was removed.
Mouse ventricles were washed in cold PBS and homogenized in RIPA containing protease inhibitor PMSF for 5 min at ice. The homogenates were centrifuged at 12, 000 r/min for 20 min in 4°C. Supernatant was collected and stored at -80°C. 
Enzyme-linked immunosorbent assay (ELISA)
The supernatant of cell culture was collected. IL-1, IL-6, IL-18, and TNF- were determined by the enzyme-linked immunosorbent assay (ELISA) following the instructions of the provider (Elabscience, Wuhan, China). After color development, the optical density at 450 nm was determined by microplate reader Epoch 2 (BioTek, Winooski, VT). To determine mouse IL-1, IL-6, IL-18, and TNF-, mouse hearts were collected and homogenized. The supernatant was collected for ELISA.
Histopathology
Mouse hearts were collected and the ventricles were fixed and embedded in paraffin. Cardiac tissues were sectioned and subjected to HE staining as described previously . Tissue sections were analyzed separately by two specialists in the Department of Pathology of Harbin Medical University.
Cell viability
HeLa cells were seeded in 96-well plates and treated with NAC (Sigma-Aldrich) at various concentrations for 24 h. Cell viability was determined using Cell Counting Kit-8 (CCK-8) (Beyotime, Wuhan, China) in accordance with the protocol of the provider. In brief, after the incubation period, the culture medium was removed and fresh medium with 20 μl of 5 mg/ml CCK-8 reagent was added. Cells were incubated for another 2 h until the formation of formazan crystals. Cells were washed with PBS for three times, and formazan crystals were solubilized with 150 l of DMSO. Cell viability was determined using a microplate reader Epoch2 (BioTek) at 570 nm and normalized to control cells. Positive control was also provided by the manufacturer.
Measurement of ROS production
To measure ROS production, cells were pre-treated with NAC at 20 mM for 1 h and infected with CVB3 (MOI =1) for 24 h. Cells were incubated with 10 µM DCF-DA (Beyotime, Wuhan, China), a fluorogenic dye that measures hydroxyl, peroxyl and other ROS activities within the cell, for 30 min. Cells were then washed twice with ice-cold PBS followed the observation of by Leica DM2000 fluorescence microscope (Germany) at the wavelength of 485/520 nm (absorption/emission). Fluorescence intensity was calculated with the ImageJ.
Caspase-1 activity assay
Caspase-1 activity was measured using Caspase 1 Activity Assay Kit (Solarbio, Beijing, China) according to the instruction of the manufacturer. 10 unit of active recombinant human caspase-1 protein (ab39901, Abcam; Cambridge, MA) and 50 nM NAC were added to the reaction buffer, which was incubated at 37 °C for 2 h. A standard curve was prepared. The optical density was read on a microplate reader (Epoch2, BioTek) at 405 nm.
Statistical analysis
In vitro experiments were repeated at least four times. Animal experiments were repeated three times with 6 to 9 mice per treatment group. Quantitative data are presented as mean ± SD. Student t test was used to compare the results. P value of less than 0.05 is considered as statistically significant. Data were analyzed by Graphpad Prism 8.
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